查詢結果分析
相關文獻
- Gene Therapy with Tumor Vaccine Increases the Survival of Hepatoma-Bearing Mice
- 肝癌的成因及危險因子
- 肝癌病患家屬參加教育心理團體成效探討
- N-Acetyltransferase in Healthy Human Liver and Hepatoma Tissues
- Use of Color Ultrasound in Percutaneous Intravascular Ethanol Injection into the Supplying Vessel of a Hepatocellular Carcinoma: Report of a Case
- 小型肝癌併腦部轉移
- Hepatocellular Carcinoma Presenting with Acquired Porphyria: A Case Report and Review of the Literature
- Evaluation of a Simplified Staging System for Prognosis of Hepatocellular Carcinoma
- 肝癌的危險因子
- Carcinosarcoma of the Liver: Report of a Case
頁籤選單縮合
題名 | Gene Therapy with Tumor Vaccine Increases the Survival of Hepatoma-Bearing Mice=腫瘤疫苗基因治療能有效延長肝癌小鼠存活時間之研究 |
---|---|
作者 | 趙毅; 施勇綸; 鄭心如; 魏松仁; 季匡華; 顏上惠; 李壽東; 楊文光; | 書刊名 | 中華醫學雜誌 |
卷期 | 62:10 1999.10[民88.10] |
頁次 | 頁682-689 |
分類號 | 415.138 |
關鍵詞 | 卡介苗; 顆粒-巨噬細胞族群刺激因子; 肝癌; 第二介白素; 腫瘤疫苗; Bacillus calmette-Guerin; Granulocyte-macrophage colony-stimulating factor; Hepatoma; Interleukin-2; Vaccine; |
語文 | 英文(English) |
中文摘要 | 背景 為建立預防及治療AJ小鼠H6肝癌的策略,我們發展了H6肝癌細胞腫瘤 疫苗基因治療動物模式。 方法 將含有小鼠第二介白素(IL-2)或顆粒-巨噬細胞族群剌激因子(GM-CSF)之互 補去氧核醣核酸轉入質體,再轉染於小鼠H6肝癌細胞內,並確定這些細胞是否會分泌IL-2 或GM-CSF。在預防肝癌生長實驗中,AJ小鼠分為4組,分別於每週免疫1次經放射線照 射後的H6肝癌母細胞、分泌IL-2之H6肝癌細胞(H6╱IL-2)、分泌GM-CSF之H6肝癌 細胞(H6╱GM-CSF)或H6╱IL-2和H6╱GM-CSF 1:1的混合細胞,目的使AJ小鼠成為 “免疫小鼠”。3週後,在“免疫小鼠”背部接種活的H6肝癌細胞,並分別記錄背部肝癌 生長的大小。3天後,AJ小鼠分為8組,再接種經放射線照後的H6肝癌母細胞±BCG、H6 ╱IL-2±BCG、H6╱GM-CSF±BCG或1:1[H6╱IL-2+H6╱GM-CSF] ±BCG,並記錄AJ 小鼠背部肝癌的大小。 結果 在預防肝癌生長實驗中發現,接種H6肝癌母細胞之小鼠無法抑制肝癌的生長; 但其它3組中之小鼠則能形成免疫力,並可抑制再接種的活H6肝癌細胞形成肝癌。另外在 治療肝癌生長實驗中還發現,與其它種瘤疫苗治療組比較,H6╱GM-CSF+BCG腫瘤疫苗治 療組延緩已形成之肝癌的生長。 結論 由以上結果可知:(1)肝癌腫瘤疫苗可有效地預防肝癌生長。(2)BCG合併H6 ╱GM-CSF治療對延遲已形成之H6肝癌生長有加成作用。 |
英文摘要 | Background. Tumor vaccines combined with cytokine gene therapy and Bacillus Calmette- Guerin (BCG) were tested for prevention and therapeutic effects in the H6 mouse hepatoma model. Methods. Plasmid DNA of expression vectors carrying cDNA of mouse interleukin (IL)-2 and mouse granulocyte-macrophage colony-stimulating factor (mGM-CSF) were used for transfection to obtain H6 mouse hepatoma cells that secreted IL-2 (H6/IL-2) or GM-CSF (H6/GM-CSF). For tumor prevention, groups of mice were immunized twice with irradiated tumor cells with untransduced H6, H6/IL-2, H6/GM-CSF, or and equal mixture of H6/IL-2 and H6/GM-CSF. Three weeks later, these mice were inoculated subcutaneously with live H6 hepatoma cells, and tumor growth was measured. For therapeutic studies, mice first inoculated with live H6 cells were treated three days later with various irradiated tumor cell vaccines alone or in combination with BCG. Subsequent tumor growth was measured. Results. In tumor prevention studies, significant protection from tumor growth has been observed in animals vaccinated with irradiated cytokine-secreting H6 cells compared with those iimmunized with irradiated parental H6 cells. In tumor therapy studies, subsequent administration of irradiated H6/GM-CSF cells in combination with BCG impeded the tumorigenicity of preinoculated live H6 hepatoma cells. Conclusions. These results suggest that cytokine-secreting tumor vaccines have a prophylactic effect and BCG, in combination with irradiated H6/GM-CSF cells, shows a synergistic effect on delaying the growth of H6 mouse hepatomas. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。